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were done to evaluate memory (Morris water maze and elevated 
plus maze task), exploratory behavior and anxiety (Open field test) 
and locomotion (actophotometer). The rats were sacrificed on day 
43 after the last behavioral test. Markers for cellular oxidative stress, 
mitochondrial oxidative parameters, acetylcholine esterase activity, 
and aluminum concentration in the brain tissue were assessed.
Results: Chronic aluminium chloride treatment caused cognitive 
dysfunction (as shown by behavioral tasks) and mitochondrial 
and cellular oxidative damage compared with the vehicle-treated 
control group. Besides, aluminium chloride treatment significantly 
increased acetyl cholinesterase activity and aluminum concentration 
in the brain compared with control. Coadministration of 4-ME sig-
nificantly improved cognitive performance and attenuated cellular 
and mitochondrial oxidative damage, acetyl cholinesterase activity 
and aluminum concentration in aluminium-treated rats. Only 4-ME 
treatment for 42 days did not alter the studied parameters in rats.
Conclusion: Results of the study demonstrate neuroprotective poten-
tial of 4-ME against aluminium chloride–induced neurodegeneration. 
Thus, 4-ME can be a promising candidate in the management of 
Alzheimer’s disease.
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Introduction: Studies have suggested neurotoxic effects of amyloid 
β protein and oxidative stress in Alzheimer’s disease. In the present 
study, we have analyzed the effect of a diet rich in figs for 1 year on 
behavior abnormalities in AppSw 2576 AD transgenic mouse model.
Patients (or Materials) and Methods: The experimental groups of 
APP-transgenic mice from the age of 4 months were fed custom-mix 
diets (pellets) containing 4% figs. These experimental and control mice 
behavior status were examined every 3 months for a period of 1 year 
by Morris water maze test (for spatial memory and learning ability), 
T maze test (for position discrimination learning ability), rota rod test 
(for psychomotor coordination), elevated plus maze test and open field 
(for anxiety-related behavior), and open field test to analyze the effect 
of fig-rich diet rich on memory, anxiety, and learning skills.
Results: APPsw/Tg2576 mice fed with the control diet showed a 
trend of memory deficit, anxiety-related behavior, and severe impair-
ment in spatial learning ability, position discrimination learning abil-
ity and motor coordination compared with the wild-type mice on the 
same diet. The fig-rich diet fed AD mice showed significant behavior 
improvement when compared with AD Tg mice.
Conclusion: Our results suggest that long term supplementation of 
fig in the diet might have the beneficial effect in reducing the risk, 
delaying the onset or slowing the progression of Alzheimer’s disease 
and also our results suggest that further studies are needed to validate 
and determine the mechanism of action of these fruits against AD.
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Introduction: To determine the prevalence of drug-induced long QT 
at admission to a public psychiatric hospital and document associated 
factors in a cross-sectional approach.
Patients (or Materials) and Methods: All ECG recordings over a 
5-year period were reviewed for drug-induced long QT (QTc ≥ 500 
ms; certain or probable drug imputability) and associated conditions. 
Patients with drug-induced long QT (n = 62) were compared with a 
sample of patients with normal ECG (n = 143).
Results: Among 6790 inpatients, 27.3% had abnormal ECG, 1.6% 
had long QT, and 0.9% were detected as drug-induced long QT 
cases. Sudden cardiac death was recorded in 5 patients and torsades 
de pointes in 7 other patients. Drug-induced long QT patients had 
significantly higher frequencies of hypokalemia (19.4% vs 5.6%; P = 
0.004), hepatitis C virus infection (41.9% vs 9.8%; P < 0.001), HIV 
infection (24.2% vs 6.3%; P = 0.001), and abnormal T-wave mor-
phology (35.5% vs 15.4%; P = 0.003). Haloperidol, sertindole, clo-
tiapine, phenothiazines, fluoxetine, (es-) citalopram, and methadone 
were significantly more frequent in drug-induced long QT patients. 
After adjustment for hypokalemia, hepatitis C virus infection, HIV 
infection, and abnormal T-wave morphology, effects of haloperidol, 
clotiapine, phenothiazines, and (es-)citalopram remained statistically 
significant. Receiver operating characteristic curve analysis based on 
the number of endorsed factors per patient indicated that 85.5% of 
drug-induced long QT patients had ≥ 2 factors, whereas 81.1% of 
normal ECG patients had < 2 factors.
Conclusion: Drug-induced long QT and arrhythmia propensity sub-
stantially increase when specific psychotropic drugs are administered 
to patients with hypokalemia, abnormal T-wave morphology, hepa-
titis C virus infection, and HIV infection.
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Introduction: Hepatic metabolism of clomipramine (C) consists of 
demethylation into the active metabolite desmethylclomipramine 
(DC) by CYP2C19 and CYP3A4, and hydroxylation of the par-
ent drug and the metabolite catalyzed by CYP2D6. CYP2D,6 and 
CYP2C19 are characterized by genetically determined polymor-
phisms. The influence of CYP2D6 and CYP2C19 polymorphisms on 
C and DC plasma concentrations and on occurrence of adverse effects 
is well described, but its role on clinical outcome is more anecdotal.
Patients (or Materials) and Methods: We report the case of a 40-year-
old woman with severe recurrent depressive disorder, history of 
several suicide attempts, borderline personality disorder, and fibro-
myalgia, who was admitted in Geneva Psychiatric Hospital during 6 
months for her fourth suicide attempt. Oral treatments with dulox-
etine (30 mg/d), escitalopram (30 mg/d), venlafaxine (225 mg/d), and 
mirtazapine (30 mg/d) were successively tried but were considered 
ineffective. A significant improvement, observed by the caregivers 
and the patient herself, was eventually obtained with intravenous (IV) 
clomipramine (50 mg/d). The patient returned home with oral clomi-
pramine (112.5 mg/d), olanzapine (5 mg/d), flurazepam (15 mg/d), 
